GlaxoSmithKline is now in “full countdown mode” to the demerger of its Consumer Healthcare business, according to CEO Emma Walmsley.
Two months on from GSK’s rejection of a £50bn ($68bn) bid for the business from Unilever – and with other suitors seemingly yet to materialize – Walmsley is pressing ahead...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?